OKYO Pharma Ltd current report, Q2 FY2023

Full document

OKYO Pharma Ltd. Form 6-K Summary

Business Context and Reporting Period

OKYO Pharma Ltd. furnished a Form 6-K dated April 4, 2023. The filing reports a corporate listing action rather than financial results. The company is a foreign private issuer that files annual reports on Form 20-F.

Material Corporate Action

  • The company applied to the UK Financial Conduct Authority and London Stock Exchange plc to cancel the listing of its ordinary shares on the standard segment of the FCA Official List and their trading on the LSE Main Market.
  • The proposed cancellation is referred to as the “Delisting.”
  • The Delisting will not affect the company’s American Depositary Shares traded on Nasdaq.
  • Each ADS currently represents 65 ordinary shares.

Financial Metrics and Outlook

The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, guidance, or other financial metrics. It also does not provide a clear completion date or additional terms for the proposed Delisting.

Risks, Contingencies, and Unusual Items

  • The Delisting application remains subject to the relevant FCA and LSE processes and approvals; the filing does not state that the cancellation had been completed.
  • Although the company states that Nasdaq-traded ADSs will not be affected, investors should assess any potential implications for liquidity, trading arrangements, and the relationship between the ADSs and ordinary shares.
  • The announcement was furnished as Exhibit 99.1 and is not deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, nor generally incorporated by reference into other filings unless expressly stated.

Facts Investors Should Verify

  1. Whether the FCA and LSE approved the proposed Delisting and its effective date.
  2. Whether the ADSs continued trading on Nasdaq without changes to their terms or depositary arrangements.
  3. Whether the 65:1 ADS-to-ordinary-share ratio changed after the announcement.
  4. Any subsequent company disclosures regarding trading liquidity, shareholder treatment, or financial performance.